Latest news

CEO Michael Heltzen and Co-Founder & VP of Research Dr. Tyler Korman present the Invizyne story and IPO opportunity to investors

MDB Capital CEO and Invizyne board member, Chris Marlett, presents the Invizyne story and initial public offering (IPO) opportunity to investors via Zoom on June 11, 2024

The story of eXoZymes: Interview with Tyler Korman and Paul Opgenorth

Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq

Invizyne Technologies Announces Filing of Registration Statement for Proposed Offering and Listing on Nasdaq

Michael Burns Joins Invizyne as Executive Vice President of Energy Transition

Invizyne Selected by Shell GameChanger Accelerator Powered by NREL for Sixth Cohort

Invizyne Awarded Additional $3.77 Million Grant from U.S. Department of Energy

Invizyne Awarded Additional $3.77 Million Grant from U.S. Department of Energy

A bio-inspired cell-free system for cannabinoid production from inexpensive inputs

Synthetic Biochemistry: The Bio-inspired Cell-Free Approach to Commodity Chemical Production